CA-TULA-TECHNOLOGY
Tula Technology, Inc., a leader in propulsion efficiency, will put its Dynamic Motor Drive® (DMD) technology into action at the 45th International Vienna Motor Symposium on April 24-26 in Vienna, Austria. Tula has retrofitted a Tesla Model 3 with an externally excited synchronous motor (EESM) running DMD software, and this innovative strategy will be demonstrated at the conference.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240416986692/en/
Tula has retrofitted a Tesla Model 3 with an externally excited synchronous motor (EESM) running Dynamic Motor Drive® software. This innovative technology will be demonstrated at the 45th International Vienna Motor Symposium on April 24-26 in Vienna, Austria.(Photo: Business Wire)
Tula developed DMD to improve electric drive efficiency with a software-only solution. With an optimized pulsing strategy, DMD reduces energy consumption while having no perceptible impact on vehicle noise and vibration. Depending upon application, DMD with EESM can reduce energy consumption by up to 3%. This efficiency improvement can be directly translated into reduced battery size and cost, or alternatively, increased range.
Putting DMD to the test in a Tesla Model 3
Improved efficiency coupled with imperceptible operation is not only possible, Tula has now proven the feasibility of DMD in two vehicles with fundamentally different electric propulsion systems. In its latest effort, Tula retrofitted the permanent magnet synchronous motor (PMSM) in a Tesla Model 3 with a wound rotor to create an EESM. Tula then incorporated its proprietary DMD control logic to reduce energy consumption and improve overall system efficiency.
In 2022, Tula’s initial DMD application utilized a Chevrolet Bolt with an unmodified PMSM drive unit. Testing showed that DMD meaningfully improved the Bolt’s energy consumption while maintaining drive quality, demonstrating the value of DMD in PMSM applications.
DMD’s role in tomorrow’s powertrain
Improving the efficiency and lowering the cost of electric vehicle powertrains is one of the most critical challenges facing the automotive world today. Further, when developing powertrains for the future, manufacturers will increasingly seek to reduce their dependence on problematic rare earth elements. The combination of EESM and DMD supports that goal while being highly competitive in terms of both efficiency and cost. Although many motors will still be PMSM, Tula’s DMD technology also provides a high-value efficiency gain there. Overall, DMD is a scalable, adaptable, cost competitive and sustainable solution that makes electrified propulsion systems more efficient, accelerating the transition to an electrified future.
Members of Tula’s DMD development team will present a paper on their DMD findings at the Vienna Motor Symposium.
About Tula Technology, Inc.
Silicon Valley-based Tula Technology provides innovative award-winning software controls to optimize propulsion efficiency and emissions across the mobility spectrum, including electric, hybrid, gasoline, diesel, and alternative fuel vehicles. Tula’s culture of innovation has resulted in breakthrough technologies and a robust global patent portfolio of more than 400 patents issued and pending. Tula Technology is a privately held company backed by Sequoia Capital, Sigma Partners, Khosla Ventures, GM Ventures, BorgWarner and Franklin Templeton. More information is available at www.tulatech.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240416986692/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Acuity Knowledge Partners Acquires Ascent18.9.2025 09:30:00 CEST | Press release
Acuity Knowledge Partners (Acuity), a leading global provider of bespoke research, data management, analytics and AI solutions to the financial services sector, has announced that it has exchanged on the acquisition of Ascent. The transaction is expected to close on 30th September 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250915732380/en/ L-R: Stewart Smythe, Chief Executive Officer, Ascent; Jon O'Donnell, Chief Operating Officer, Acuity Knowledge Partners, and Robert King, Chief Executive Officer, Acuity Knowledge Partners This strategic move significantly expands Acuity's Data and Technology Services (DTS) division and its offering of technology and AI led services and solutions. Ascent, a leading European provider of AI-powered digital transformation services, supports over 170 clients globally, with 550 data, software, and cloud specialists operating across seven European jurisdictions. “Our acquisition of Asc
Shield and PwC UK Forge Strategic Collaboration to Deliver Future-Ready Communications Compliance18.9.2025 08:00:00 CEST | Press release
Collaboration brings together Shield's AI-first platform with PwC's surveillance expertise to deliver measurable compliance outcomes Shield, a leading AI platform for digital communication governance and archiving, today announced a collaboration with PwC UK, one of the world’s most trusted professional services firms. The alliance brings together Shield’s unified, cloud-native solution with PwC’s specialist expertise in communications surveillance delivery, regulatory compliance and complex programme execution. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250917394739/en/ Shield and PwC launch a strategic collaboration to modernize eComms surveillance with AI-driven compliance solutions for financial institutions. The collaboration is designed to support institutions as they modernise their approach to communications monitoring, helping them implement an advanced and proactive risk management approach at scale and with co
Almirall Presents Long‑Term Results from First Real‑World Dermatology Study Using WHO‑5 Well‑Being Index as Primary Endpoint in the treatment of Psoriasis at EADV 202518.9.2025 08:00:00 CEST | Press release
Results of the POSITIVE study assessing the treatment with tildrakizumab showed sustained improvements in skin clearance, psychological well-being, and improved partner quality of life in adults with moderate-to-severe psoriasis over two years.POSITIVE is the first real-world evidence (RWE) study in dermatology to use the WHO-5 Well-Being Index as a primary endpoint, complementing traditional measures of skin disease (PASI, PGA), quality of life (DLQI), with the assessment of psychological well-being, marking a paradigm shift towards holistic management of psoriasis.The POSITIVE study highlights Almirall’s leadership in advancing patient-centred dermatology aligned with the WHO’s health definition and recent resolution on skin diseases.Almirall’s extensive scientific contributions to EADV 2025 include 44 abstracts across key dermatological conditions including atopic dermatitis, psoriasis, actinic keratosis, and hidradenitis suppurativa, and two expert-led symposia. Almirall, S.A. (ALM
Curatis: FDA Minutes Confirm Positive Outcome of Meeting on 9. September 2025 – Corticorelin on Track for Phase 318.9.2025 07:00:00 CEST | Press release
Curatis Holding AG (SIX:CURN) received the official minutes from the FDA meeting which took place on 9. September. Based on the totality of the feedback and discussions, Curatis can proceed as planned with the clinical development of corticorelin. Corticorelin is under development as a novel treatment intended to reduce or even eliminate steroid use and associated toxicities thereby potentially impacting the quality of life of patients suffering from peritumoral brain edema (PTBE) associated with metastatic (secondary) brain tumors. The virtual meeting with the FDA provided the opportunity to discuss the clinical development plan for corticorelin and encompassed CMC (Chemistry, Manufacturing and Control), nonclinical and clinical aspects. The offical FDA minutes which Curatis received after publication of the half year results reflect the positive outcome. Curatis may proceed without delay to a regulatory submission supporting a pivotal study in patients suffering from PTBE secondary t
Galderma Launches Transformative Skincare Segment With Cetaphil’s New Skin Activator Hydrating & Firming Line, in Partnership With Actor and Filmmaker Mariska Hargitay18.9.2025 07:00:00 CEST | Press release
Cetaphil's new Skin Activator Hydrating & Firming Line harnesses a proprietary formula, co-created with dermatologists and offering targeted, high-performance skincare designed to improve the appearance of skin affected by dermatoporosis The line’s new Skin Activator technology uses microdosed alpha hydroxy acid (AHA) and encapsulated centella asiatica (CICA) to wake up sleeping surface skin cells To help bring this segment-defining product line to life, Cetaphil is partnering with acclaimed actress, director, and advocate, Mariska Hargitay, a powerful voice in embracing beauty at every stage Galderma today announced Cetaphil, the dermatologist-recommended brand trusted by millions with sensitive skin, is redefining daily skincare with its new Skin Activator Hydrating & Firming line. The launch marks an entirely new skincare segment of advanced hydration and firming solutions designed specifically for improving the appearance of aging, thinning, and fragile skin. As people age, surface
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom